Companies · NVS
Novartis
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Sep 4, 2026
Novartis pelacarsen misses cardiovascular outcomes primary endpoint in Phase III Lp(a)HORIZON trial
Novartis announced that pelacarsen, an investigational antisense oligonucleotide targeting lipoprotein(a), failed to meet the primary endpoint of reducing cardiovascular events in the Phase III Lp(a)HORIZON trial despite achieving lower Lp(a) levels. The trial enrolled 8,323 patients with elevated Lp(a) and established cardiovascular disease, testing whether Lp(a) lowering could reduce residual cardiovascular risk beyond guideline-directed therapy. This negative outcome eliminates pelacarsen as a marketed cardiovascular therapeutic and signals that Lp(a) reduction alone, in the presence of optimized guideline-directed care, does not translate to clinical benefit—a structural finding that reshapes the validation case for the Lp(a) target class.
Tone: defensiveRevenue
$56.7B
NVS 20-F · FY 2025
Employees
75,267
Revenue FY2024
$51.7B
Founded
1996
Profile
NVS 20-F Item 4.B · Feb 4, 2026Novartis is a Swiss-based global innovative medicines company focused on research, development, manufacturing, and commercialization of pharmaceutical products across four core therapeutic areas: cardiovascular, renal and metabolic; immunology; neuroscience; and oncology. The company sells products in approximately 120 countries and employs over 75,000 full-time equivalent employees. Its strategy centers on technology leadership in R&D and novel access approaches to deliver high-value medicines.
Read filing description ↓ Collapse description ↑
Novartis is an innovative medicines company, engaged in the research, development, manufacturing, distribution, marketing and sale of a broad range of pharmaceutical products. Our purpose is to reimagine medicine to improve and extend people's lives. Our strategy is to deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. To support our strategy, we have clear focus areas where we commit most of our time, energy and resources. These core therapeutic areas are cardiovascular, renal and metabolic; immunology; neuroscience; and oncology. In 2025, Novartis achieved net sales from continuing operations of USD 54.5 billion, and net income from continuing operations amounted to USD 14.0 billion. Headquartered in Basel, Switzerland, we employed 75 267 full-time equivalent employees as of December 31, 2025. Our products are sold in approximately 120 countries around the world. Our operations are organized into the following five organizational units: Biomedical Research, Development, Operations, and two commercial units, US and International. These organizational units are supported by our global functions in areas such as corporate affairs, ethics, risk and compliance, finance, legal, internal audit, people and organization and strategy and growth.
Primary products
- Entresto (sacubitril/valsartan)
- Cosentyx (secukinumab)
- Kisqali (ribociclib)
- Kesimpta (ofatumumab)
- Tafinlar + Mekinist (dabrafenib + trametinib)
- Jakavi (ruxolitinib)
Business segments
End markets
Geographies
Named competitors
“The global pharmaceutical market is highly competitive. We compete against other major international corporations that have substantial financial and other resources, as well as against smaller companies that operate regionally or nationally.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Reported in USD. Net sales from continuing operations grew 8% in both USD reported terms and constant currencies in 2025, driven by 15 percentage points of volume growth, partially offset by 6 percentage points of generic competition headwind and 1 percentage point of pricing pressure.
The rest of NVS is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.